Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Managed to top up, however N/T to buy. This is going to pop as no one will want to sell before news.
I wonder if another fund is selling their shares, seems weird that both days this week by 11-12 that we are down 10%.
Independent Non-executive Director on twitter: The answer should come from HKEx 4 weeks from submission. We are expecting to have an update next week at latest. The China/USA news does not seem to adversely affect the HK market.
Does it mean that we should be due a tender offer for our shares?
Topmoney I too have become increasingly anxious as the weeks have passed, as I thought we would be listed come the end of May. However, I have gone through the recent RNS's regarding delisting and the 3 month relisting window is from the date that resolution 6 was passed and not when we resubmitted the application. Going on this date we are in fact only 5 weeks into the 3 month window, I would agree with you though it is rather frustrating having no updates at all. The company has a robust order book and sound financials, therefore I am still positive that relisting will go ahead it's just a waiting game now. Best of luck all.
https://www.hkex.com.hk/Listing/Getting-Started/Listing-on-the-Main-Board?sc_lang=en
I wonder if we're at stage 6?
FYI the listing committee meet once a week to discuss such matters, so at least they meet very regularly.
10 Companies were granted approval in principle for listing on the HKEX in April. Lets hope that we were one of those companies!
Scotlouie, I copied and pasted this from a message HL sent me. I hope that this helps!
Hargreaves Lansdown uses the UK Central Securities Depository, CREST, for all equity and bond settlement and if a stock is withdrawn or cannot be held through CREST it restricts the trading options available to Hargreaves Lansdown clients.
In order to provide an on-going dealing facility in China New Energy Ltd Shares we have entered a global custody agreement with HSBC Bank plc. This agreement means that the stock can be held in its relevant overseas settlement system which ensures that trades in the stock can be settled. The Shares will continue to show in your Hargreaves Lansdown portfolio, but as the underlying custodian will be HSBC, or a sub-custodian of HSBC, there will be certain implications you should be aware of.
Whilst the stock is held with HSBC we will only allow sale instructions to be processed and all purchase requests will be rejected. It will only be possible to sell the Shares by phoning our Stockbrokers on 0117 980 9800, subject to telephone dealing rates of 1% of the consideration, subject to a minimum of £20 and a maximum of £50. Trades will be placed in Hong Kong Dollars and converted by Hargreaves Lansdown subject to our standard currency conversion fees.
Our Hong Kong broker will also charge a commission fee of HKD1,000.00 (currently approximately £100), which will be passed on to you.
Harbour are involved with the Netherlands work:
https://www.nature.com/articles/s41467-020-16256-y#Bib1
Look at the Author Information section, more specifically the affiliation and contributions sub sections.
The company tweeted on 21st April 2020:
Based on our own test of the presence of anti-#SARSCoV2 #antibodies in the peripheral blood, all full-time employees of #Hemogenyx are negative. It likely means that #Hemogenyx #scientists did not have #COVID?19. #StaySafe
This tweet seems to indicate that the company has isolated an antibody against the virus. The test they have developed tests for the presence of ANTI SARSCoV2 antibodies. In addition, they use the phrase "likely means that #Hemogenyx #scientists did not have #COVID". This implies that this is the antibody that is produced as a natural response when the body is exposed to COVID-19, therefore likely the antibody that would be used as a neutralizing agent for a treatment against the virus.
Obviously that is my interpretation of the tweet and may not be the cases at all. Best of luck all!
"BARDA’s partnership with J&J encompasses research and development of potential antiviral treatments in addition to the work that’s being done to develop a vaccine for the disease. Those efforts include development work J&J and BARDA are conducting with the Rega Institute for Medical Research in Belgium."
Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.
I wonder if this means anything?
Hi All,
With the ample amount of time I currently have on my hands, I decided to do some further investigation into HKEX listing. China New Energy Limited submitted its application on the 27/03/2020, the HKEX official website states that the average date the first comment letter is issued is 21 working days after the submission date. The first comment letter are the first letters issued by Listing Department staff that contain the comments on the respective listing applications. Since submitting our application and the Convertible Loan Extension RNS, 24 working days elapsed. The fact the 21 day average has already elapsed and we have agreed to convert the loan into ordinary shares listed on the HKEX, suggests we have received the first comment letter already. Furthermore, this letter must have been a very positive response, otherwise why issue HKEX shares? This suggests to me that the relisting has been approved in principle and that we should get a confirmation RNS by the end of May at the latest. As ever DYOR.
Regards,
Gdale1997
Personally I think that we will see a gradual increase in the share price, as we get closer to the predicted listing date (end of Q1). More people will take a positions due to the good risk vs reward that the relisting endeavour presents, as we have previously discussed on this page. However, with the historic lack of communications from the company, I think the next thing we will hear is either; there are 10 days until relisting or that the company was unsuccessful again. Best of luck all!
This is their second submission for the listing, so you would imagine they have improved PoA to achieve the MCAP. As this is effectively an IPO on the HK exchange, I personally don't think they will struggle getting people to buy the stock. This is the whole reason why they want to relist, as they believe they will achieve a greater access to capital having a listing more proximal to where they conduct their business.
As Investor81 mentioned, the risk to reward here is really does favour PI's. I hold £1,500 of shares, if we don't receive approval I may lose half my investment, on the flipside there is potential to make in excess of £3000 profit within 3 months. Best of luck to you all!
My opinion is that this RNS reiterates the idea that the HK listing is nailed on to go ahead. Double River Limited are receiving shares at the value of 5p, you would imagine that this is at a favourable discounted price. Currently the MCAP is £11 million (2.5p a share), to list on the HK exchange the minimum MCAP must be £50 million. Therefore, when the company IPO's on the exchange you would expect a minimum price of 11.36p a share, which is over 4 times the current price. These figures indicate that Double River are in fact receiving such shares at around a 50% discounted price.
Last two candles on the chart appear to form a bullish engulfing pattern. Indicating that buying pressure has overpowered selling pressure. DOJI’s in the past few candles indicated that this was previously balanced. Hopefully signalling a trend reversal and over the next couple of sessions we see a steady increase in share price.
I’ve noticed that all large buying and selling seems to have dried up. My prediction is potentially one huge trade appearing in the next couple of days/week. This will be accompanied with a TR1. This is only a prediction and not to be taken seriously. GLA.